Nvidia Stock Outlook Brightens on Vera Rubin Ramp

Nvidia stock outlook brightens as Vera Rubin system specs, production ramp and partner timelines point to accelerating GPU demand and tighter supply.

March 23, 2026·2 min read
View all news articles
Flat vector of a Vera Rubin server rack symbolizing the production ramp and Nvidia stock outlook

KEY TAKEAWAYS

  • CEO projected $1 trillion in cumulative Blackwell and Vera Rubin orders through end-2027.
  • Vera Rubin NVL72 was in full production and slated to ship in the second half of 2026.
  • Company and partners described supply capacity to produce thousands of systems per week supporting sustained GPU revenue growth.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Nvidia (NVDA) said at its GTC conference that management expects large cumulative orders for its next-generation AI platforms, a projection executives said will tighten hardware supply and improve the Nvidia stock outlook by boosting demand for GPUs.

Orders and Market Outlook

CEO Jensen Huang projected cumulative orders for Nvidia’s Blackwell and Vera Rubin AI platforms through the end of 2027, totaling $1 trillion. Executives described this as a multi-year platform opportunity that could reshape revenue dynamics. They said demand will exceed supply and that the company’s technical scale and partner schedules support a sustained increase in GPU revenue.

Vera Rubin Systems and Production

Nvidia detailed the Vera Rubin POD as a rack-scale AI supercomputer with 40 racks, about 1.2 quadrillion transistors, nearly 20,000 dies, and 1,152 Rubin GPUs. It delivers roughly 60 exaflops of performance and 10 petabytes per second of internal bandwidth. The POD supports five rack-scale variants—NVL72, LPX, CPU, STX, and CMX—designed for agentic AI workloads. The NVL72 racks link 72 Rubin GPUs with 36 Vera CPUs via NVLink, offering four times the training and ten times the inference performance per watt compared with Blackwell GPUs. Nvidia said the NVL72 is in full production and on track to ship in the second half of 2026. The company also introduced a Vera Rubin Space Module for orbital data centers and launched the Neatron coalition to support open AI models.

Partner Availability and Supply

HPE announced it will offer the Vera Rubin NVL72 in December 2026 and plans to release the HPE Compute XD700 configured for Vera Rubin in early 2027. Supermicro confirmed support for Vera Rubin configurations across its DCBBS, HGX Rubin NVL8, and Vera CPU platforms. Company and partner materials indicate supply-chain capacity sufficient to produce thousands of Vera Rubin systems per week, describing a manufacturing footprint equivalent to multiple gigawatt-scale AI factories per month to reach volume output.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Prediction Markets Ban Spurs Gambling Stocks Rally

Prediction Markets Ban Spurs Gambling Stocks Rally

Reports of a prediction markets ban on March 23 lifted DraftKings, Entain and MGM as traders priced reduced competition from prediction platforms.

Terafab Chip Plant Austin Planned by Tesla and SpaceX

Terafab Chip Plant Austin Planned by Tesla and SpaceX

Terafab chip plant Austin is a $20 billion Tesla and SpaceX bet that could prompt traders to reprice chip supplier exposure and capacity assumptions.

U.S. Stocks Surge After Trump Pauses Iran Strikes

U.S. Stocks Surge After Trump Pauses Iran Strikes

U.S. stocks surge after President Trump announced a pause on planned strikes against Iranian power plants, sending futures higher and oil lower.

Palantir Maven Program of Record Lifts Stock

Palantir Maven Program of Record Lifts Stock

Palantir Maven Program of Record formalizes DoD battlefield use, moves oversight to CDAO and contracting to the Army, prompting investor repricing.

Pfizer Lyme Disease Vaccine Seeks Approval

Pfizer Lyme Disease Vaccine Seeks Approval

Pfizer Lyme disease vaccine showed strong late-stage efficacy; companies plan submissions despite missing the primary endpoint, creating investor risk.

Elliott Stake in Synopsys Seeks Higher Margins

Elliott Stake in Synopsys Seeks Higher Margins

Elliott stake in Synopsys signals a push to lift software monetization and margins, likely prompting investor engagement and trading flows.